Article
Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers.
Cancer discovery - 2 Dec 2024
Loi Patrick, Schade Amy E, Rodriguez Carrie L, Krishnan Anjana, Perurena Naiara, Nguyen Van T M, Xu Yilin, Watanabe Marina, Davis Rachel A, Gardner Alycia, Pilla Natalie F, Mattioli Kaia, Popow Olesja, Gunduz Nuray, Lannagan Tamsin R M, Fitzgerald Samantha, Sicinska Ewa T, Lin Jia-Ren, Tan William, Brais Lauren K, Haigis Kevin M, Giannakis Marios, Ng Kimmie, Santagata Sandro, Helin Kristian, Sansom Owen J, Cichowski Karen
Abstract excerpt
SIGNIFICANCE: Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
